PARUCH, Kamil, Timothy GUZI, Michael DWYER, Ronald DOLL and Viyyoor GIRIJAVALLABHAN. Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors. 2004.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors
Name in Czech Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors
Authors PARUCH, Kamil (203 Czech Republic, guarantor), Timothy GUZI (840 United States of America), Michael DWYER (840 United States of America), Ronald DOLL (840 United States of America) and Viyyoor GIRIJAVALLABHAN (840 United States of America).
Edition Number: WO 2004/026310 A1. Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering-Plough, 2004.
Other information
Original language English
Type of outcome Patent
Field of Study 10401 Organic chemistry
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/04:00035994
Organization unit Faculty of Science
Keywords (in Czech) cyclin dependent kinase; imidazopyrazine; inhibitor
Keywords in English cyclin dependent kinase; imidazopyrazine; inhibitor
Tags Cyclin dependent kinase, imidazopyrazine, inhibitor
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 25/6/2009 10:07.
Abstract
In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. I [R = CF3, (un)substituted-alkyl, -heteroaryl, -heteroarylalkyl, -cycloalkyl, -heterocyclyl, etc.; R1 = H, halo or alkyl; R2 = H, halo, CN, cycloalkyl, heterocyclyl, alkynyl and CF3; R3 = aryl (with exception of Ph), (un)subsituted-heteroaryl (with exception of furyl), -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by substitution of 8-chloro-6-methylimidzol[1,2-a]pyrazine with 3-(aminomethyl)pyridine. Methods for performing assays with I are described (no data).
Abstract (in Czech)
viz Anotace
PrintDisplayed: 2/8/2024 23:20